Literature DB >> 27480664

Haematological cancer: Anti-BCMA CAR T cells show promise in MM.

Peter Sidaway.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27480664     DOI： 10.1038/nrclinonc.2016.125

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.

Authors:  Syed Abbas Ali; Victoria Shi; Irina Maric; Michael Wang; David F Stroncek; Jeremy J Rose; Jennifer N Brudno; Maryalice Stetler-Stevenson; Steven A Feldman; Brenna G Hansen; Vicki S Fellowes; Frances T Hakim; Ronald E Gress; James N Kochenderfer
Journal:  Blood       Date:  2016-07-13       Impact factor: 22.113
  1 in total
  3 in total

Review 1.  The Multi-Purpose Tool of Tumor Immunotherapy: Gene-Engineered T Cells.

Authors:  Zeming Mo; Peixin Du; Guoping Wang; Yongsheng Wang
Journal:  J Cancer       Date:  2017-06-23       Impact factor: 4.207

2.  Infusion of chimeric antigen receptor T cells against dual targets of CD19 and B-cell maturation antigen for the treatment of refractory multiple myeloma.

Authors:  Fang Tang; Yin Lu; Yongqin Ge; Jingjing Shang; Xiaming Zhu
Journal:  J Int Med Res       Date:  2020-01       Impact factor: 1.671

3.  CAR-T Cells Based on Novel BCMA Monoclonal Antibody Block Multiple Myeloma Cell Growth.

Authors:  Robert Berahovich; Hua Zhou; Shirley Xu; Yuehua Wei; Jasper Guan; Jian Guan; Hizkia Harto; Shuxiang Fu; Kaihuai Yang; Shuying Zhu; Le Li; Lijun Wu; Vita Golubovskaya
Journal:  Cancers (Basel)       Date:  2018-09-11       Impact factor: 6.639
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.